: iStockAnalyst.com Symbols Feed

DATATRAK: Low Valuation, Improving Results

Tue, 13 Oct 2009 18:45:44 GMT

DATATRAK International Inc. (OTC: DATA.PK) is a clinical trials information technology (IT) and services company that is focused on increasing its share of an estimated $720 million (M) Electronic Data Capture (EDC) market opportunity (with about 50% or $360M of this market still utilizing paper records that have yet to convert to make the digital conversion)[More...]

Strong Earnings Report from Buffalo Wild Wings, Phase Forward Incorporated, Teva, Zoran and Pervasive Software

Tue, 28 Jul 2009 18:47:54 GMT

Buffalo Wild Wings (BWLD), best known for its chicken wings and sports bar, sustained its growth momentum in the second quarter of 2009, despite economic turmoil and rising unemployment, and affirmed its growth target of 15% in units, 25% in revenue, and 20% to 25% in net earnings, showing its resilience in a turbulent environment. ? ? The company’s second quarter 2009 profit soared 24.2% year over year to $7.0 million. As a result, EPS jumped 25.8% to $0.39, surpassing street estimate by $0.05.?Menu price increases, new restaurant openings and operational focus on product preparation drove the growth in EPS. The restaurant chain was able to increase its menu pricing when other restaurant operators were offering discounts to woo consumers during the recession. Total revenue climbed 32.4% to[More...]

Analyst Comments: Joy Global, Photronics, Martha Stewart, Kellogg, Red Robin, Cirrus Logic, Safeway, PACCAR, Celgene, AstraZeneca, Phase Forward, Digital River, Methanex, Grupo Televisa, HSBC, AAR Corp, Centennial, Carmike Cinema, Washington Post

Fri, 10 Oct 2008 14:05:00 GMT

We are maintaining our Buy recommendation on Joy Global (JOYG). The global coal market appears strong as supply and demand fundamentals should keep prices elevated for the next several years. This will be a benefit to Joy as it is the world's leading manufacturer of mining machinery in the world. Sales and bookings were impressive in Q3 reflecting producer's positive long-term outlook for coal prices. Joy's industry leading operating margins look to improve on the back of several cost cutting and capacity expansion initiatives that will be felt as early as 2009. However we are lowering our target price from $84.00 to $71.00 per share due contraction of our valuation multiples. Although already an industry leader in operating margins, the growth and cost initiatives put in place will pave the way for higher revenues, margins and[More...]

A Gem of a Natural Gas Stock

Tue, 27 May 2008 16:08:10 GMT

when looking for winners you want growth and growth is what we have here[More...]

Analyst Comments: PS Business Parks, Phase Forward, Raytheon, El Paso, Daimler, Patterson-UTI, ArthroCare

Thu, 10 Apr 2008 22:03:46 GMT

PS Business Parks, Inc. (PSB) reported good 4Q07 and full year 2007 results primarily due to better performance at current properties and new acquisitions. Same-store occupancy and rental income increased from the year earlier levels and fundamentals in the company's major markets are holding up relatively well. The increase in FFO [funds from operations] in 2007 was due to improved property operating results and new acquisitions. Same-store revenue and NOI increased...[More...]

Opening Updates

Mon, 07 Jan 2008 16:00:36 GMT

Markets have started the day higher but tough to see where they are going from here as lots of cross currents are rippling around the tape.The DJIA is acting well with 23 of the 30 components in the green led by MO VZ HD and KO...[More...]

AFTERNOON SNOOZE

Fri, 14 Dec 2007 20:02:14 GMT

Markets continue to trade lower after an initial attempt at a morning rally failed. The DJIA-100, NAZ -15 and SPX -11. Strongest...[More...]

Monday Morning - Nov 19 2007 10:21AM

Mon, 19 Nov 2007 14:16:00 GMT

Following Friday's surprising late-session rally, futures indicate a lower open for the mkt amid weakness in Asia, a downgrade of Citigroup (C) and a Q4 earnings warning from home improvement retailer Lowe's (LOW). Dow futures are currently ; Nasdaq futures are currently ; S&P futures are currently . Mkts in Asia closed lower after China's banking regulator told banks to cool loan growth that's already topped its target ceiling of 15% this year. Note, though, that the WSJ reported this morning that Chinese regulators have actually ordered China's commercial banks to freeze lending through the end of the year. In the financial sector, Goldman Sachs downgraded Citigroup to Sell, while cutting its price ests on a number of brokers, including MER, MS, LEH, BSC, JPM and ETFC. It's also worth noting that the Sunday Times reported over the weekend that Royal Bank of Scotland (RBS) CEO Fred Goodwin has been informally approached by Citigroup to become its new CEO. Lowe's reported mixed[More...]

CLOSING NUMBERS - Nov 6 2007 5:01PM

Tue, 06 Nov 2007 20:55:44 GMT

Nice gains in the closing hour gets the SPX past the 50 day SMA at the 1,520 area with sights set on the 1,535/1,540 level and the 50% retracement between 1,576 and 1,490.Strong sectors -metals, emerging markets, oils, insurance, banks and homies while airlines, internets, utils and biotechs lagged.[More...]

THE OPEN - Nov 6 2007 11:12AM

Tue, 06 Nov 2007 15:06:47 GMT

Markets opened higher but are now well off their best levels as the NAZ has flipped to red while the RUT/MID's continue and are down about .5%.Strong sectors...[More...]

Phase Forward Reports Third Quarter 2009 Results

Thu, 29 Oct 2009 20:51:00 GMT

Phase Forward Incorporated (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced its financial results for the third quarter of 2009.
Within total revenues, electronic data capture (EDC) license, application hosting and other related revenues were $38.5 million, representing 71% of third quarter total non-GAAP revenues and an increase of 18% from $32.7 million in the prior year period.
Weiler added, "During the third quarter, a pharmaceutical company in the top 40 in sales selected Phase Forward's InForm EDC solution for a multi-year, multi-million dollar commitment, while a leading provider of information technology, consulting, and business process outsourcing services selected InForm as part of their outsourcing services to a top 10 pharma.

[More...]

Phase Forward to Present at the 11th Annual Pacific Crest Technology Leadership Forum

Tue, 04 Aug 2009 20:15:00 GMT

Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced its chief financial officer, Chris Menard, and its vice president of corporate development, Martin Young, will present at the 11th Annual Pacific Crest Technology Leadership Forum at the Sonnenalp Resort in Vail, Colorado.[More...]

Phase Forward Named to FORTUNE Small Business 100 List of Fastest-Growing Public Companies

Thu, 30 Jul 2009 13:10:00 GMT

Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, is included in the FORTUNE Small Business 100 list for the second consecutive year, ranking 20th among America’s fastest-growing small public companies. Up from 38th last year, the company is also the top-ranked company in the state of Mass. and seventh among the 30 technology companies featured.[More...]

APCER Pharma Solutions, Inc. Appoints Senior Bio-Pharmaceutical Industry Executives Susan A. Jalbert and Ronald M. Lillie to U.S. Management Team

Tue, 28 Jul 2009 16:28:00 GMT

APCER Pharma Solutions, Inc. ("APCER") continues its strong U.S. expansion.
The company announced that last month it hired bio-pharmaceutical industry executives Susan A. Jalbert as Vice President of North American Sales; and Ronald M. Lillie as Client Services Director for Process Implementation, Training and Transition.
Suneet Walia, President and CEO of APCER, said, "We are building a team that brings with it excellent cross-industry experience, professionalism, and 100 percent dedication to our clients' and partners' success.

[More...]

Phase Forward Reports Second Quarter 2009 Results

Mon, 27 Jul 2009 20:56:00 GMT

Phase Forward Incorporated (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced its financial results for the second quarter of 2009.
Within total revenues, InForm license, application hosting and other related revenues were $38.2 million, representing 71% of second quarter total non-GAAP revenues and an increase of 23% from $31.1 million in the prior year period.
Bob Weiler, chairman and chief executive officer, remarked, "The company delivered better-than-expected financial results in the second quarter, in addition to renewing and expanding some of our largest customer relationships and launching a major new release of our market-leading EDC solution, InForm GTM. With the growing adoption of EDC and globalization of clinical research, end-user requirements have changed dramatically in recent years.

[More...]

Phase Forward Acquires Maaguzi LLC, Innovative Provider of Web-Based Electronic Patient Reported Outcomes (ePRO) and Late Phase Solutions

Mon, 27 Jul 2009 20:15:00 GMT

Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced it has acquired privately held Maaguzi LLC, an innovative provider of Web-based, electronic patient reported outcomes (ePRO) and late phase solutions, for $11 million in cash. Maaguzi has operations in Indianapolis, Ind. and Morrisville, N.C.[More...]

CORRECTING and REPLACING Phase Forward Agrees to Acquire Covance’s Interactive Voice and Web Response Services Business

Wed, 15 Jul 2009 16:01:00 GMT

Please note the revised Cautionary Statement paragraph.[More...]

Covance to Sell Its Interactive Voice and Web Response Services and Enter Into a Multi-Year Marketing Agreement with Phase Forward

Wed, 15 Jul 2009 13:42:00 GMT

Covance Inc. today announced it has signed an agreement to sell its Interactive Voice & Web Response Services business to Phase Forward . In addition, Covance and Phase Forward have agreed to enter into a multi-year marketing agreement to provide Phase Forward's electronic data capture solutions and IVR/IWR services to Covance clients for the next five years. Covance expects the sale, which is subject to certain closing conditions, to be completed by the end of August.In addition, Covance intends to collaborate with Phase Forward on technology that is used in the management and oversight of clinical trials such as electronic data capture, bedside data capture, electronic diaries, and other enabling technologies that have the potential to improve the efficiency of the drug development process.'Covance remains fully committed to providing our clients with integrated drug development solutions, including advanced technology for supporting clinical trials,' said Joe Herring, chairman and CEO of Covance. 'We are delighted to broaden our relationship with Phase Forward, our preferred provider of EDC software for clinical trials, to include market leading IVRS/IWRS technology for clinical trials. We believe our clients will benefit from Phase Forward's industry-leading integrated data management platform and Covance's integrated clinical trial solutions. The transaction also allows Covance's management team to focus more attention and investments on growing our service offerings in the larger markets we serve.''Covance and Phase Forward are committed to working together to deliver best-of-class solutions to our clinical trial customers,' said Bob Weiler, chairman, president and chief executive officer of Phase Forward. 'Covance has been a pioneering leader in the IVRS/IWRS market and we look forward to building upon their success. We are also delighted to solidify our long-term strategic relationship with one of the world's leading and most successful CROs.'About CovanceCovance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.7 billion, global operations in more than 25 countries, and more than 9,800 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com. About Phase Forward Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward's products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 290 organizations and regulatory agencies worldwide. Additional information about Phase Forward is available at www.phaseforward.com.Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such Forward-looking statements including the statement contained herein regarding the expected closing of the sale and anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the ability to satisfy the closing conditions to the sale, competitive factors, outstanding trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company's filings with the Securities and Exchange Commission.[More...]

Phase Forward Agrees to Acquire Covance’s Interactive Voice and Web Response Services Business

Wed, 15 Jul 2009 13:36:00 GMT

Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that it has signed an agreement to purchase the Interactive Voice & Web Response Services (IVRS/IWRS) business of Covance Inc. (NYSE: CVD) for $10 million in cash. As part of this transaction, Phase Forward and Covance have also agreed to enter into a multi-year marketing agreement to provide Phase Forward’s market leading InForm™ electronic data capture (EDC) solution and Clarix™ interactive response technology solution to Covance clients.[More...]

Phase Forward CEO Bob Weiler Presides Over NASDAQ Stock Market Opening Bell, Commemorates Company's Five Year Listing Anniversary

Tue, 14 Jul 2009 16:09:00 GMT

Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, visited the NASDAQ MarketSite in New York City's Times Square earlier today to preside over the Opening Bell and celebrate its five year anniversary of listing on The NASDAQ Stock Market.
For an archived webcast of the NASDAQ Opening Bell and high resolution photographs of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on Phase Forward/Market Open.
Members of the media interested in speaking with Phase Forward should contact Meghan Locke at 781-672-3147 or mlocke@chenpr.com.

[More...]